<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Heart Failure • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Heart Failure • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/Heart Failure/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/Heart Failure/" />

<link rel="stylesheet" href="/wiki/style.css" />

  </head>
  <body>
    <div
      class="fixed top-0 w-screen px-4 py-4 md:px-10 bg-slate-200 bg-opacity-90"
    >
    <div class="flex items-center justify-between max-w-6xl mx-auto">
      <a href="/wiki/" title="Home">
        <img src="/wiki/assets/avatar.png" class="w-10 h-10 " />
      </a>

      <nav class="flex space-x-2 uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>
    <div class="mx-auto">

    <div class="flex items-center justify-center max-w-full px-6 mt-32 mb-32">
      <div  class="prose">
<article><h1>heart failure</h1>
<ul>
<li>related: <a href="/wiki/notes/Cardiology/">Cardiology</a>, <a href="/wiki/notes/HFpEF/">HFpEF</a></li>
</ul>
<h2>Causes</h2>
<p>Drug induced cardiomyopathy includes <a href="/wiki/notes/trastuzumab%20and%20anthracycline/">trastuzumab and anthracycline</a>.
Structural causes can include <a href="/wiki/notes/Acute%20mitral%20regurgitation%20can%20cause%20acute%20heart%20failure/">acute mitral regurgitation from either ruptured chordae tendinae or papillary muscle</a>.</p>
<ul>
<li><a href="/wiki/notes/monitoring%20heart%20function%20in%20chemotherapy/">monitoring heart function in chemotherapy</a></li>
</ul>
<h2>Management</h2>
<p><a href="/wiki/notes/Management%20of%20heart%20failure%20is%20step%20wised/">Management of heart failure is step wised</a> and based on symptoms, EF, and EKG findings.</p>
<p>Selected patients can undergo <a href="/wiki/notes/cardiac%20resynchronization%20therapy/">cardiac resynchronization therapy</a> to reduce mortality.</p>
<ul>
<li><a href="/wiki/notes/Peripartum%20Cardiomyopathy/">Peripartum Cardiomyopathy</a></li>
<li><a href="/wiki/notes/athlete's%20heart%20can%20look%20like%20HCM/">athlete's heart can look like HCM</a></li>
</ul>
</article>
<hr />
<p>Backlinks</p>


<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/trastuzumab and anthracycline/" class="peer">Trastuzumab and Anthracycline</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>trastuzumab and anthracycline</h1>
<ul>
<li>related: <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<!-- medication cardiomyopathy, anthracycline vs trastuzumab -->
<p>In most patients, trastuzumab-associated cardiotoxicity is <strong>reversible</strong>; there is complete recovery of cardiac function after treatment  discontinuation. In contrast, chronic anthracycline-associated  cardiotoxicity may not be reversible after treatment discontinuation due to myocyte necrosis, destruction, and replacement by fibrous tissue.</p>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Cardiology/" class="peer">Cardiology</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>Cardiology</h1>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2>Anatomy</h2>
<h2>Physiology</h2>
<ul>
<li><a href="/wiki/notes/EKG%20basics/">EKG basics</a></li>
<li><a href="/wiki/notes/SvO2/">SvO2</a></li>
<li><a href="/wiki/notes/cardiogenic%20shock/">cardiogenic shock</a></li>
</ul>
<h2>ECGs</h2>
<ul>
<li><a href="/wiki/notes/Arrythmia/">Arrythmia</a></li>
<li><a href="/wiki/notes/bundle%20branch%20blocks/">bundle branch blocks</a></li>
<li><a href="/wiki/notes/Brugada%20syndrome/">Brugada syndrome</a></li>
<li><a href="/wiki/notes/Wellens%20syndrome/">Wellens syndrome</a></li>
</ul>
<h2>Pharmacology</h2>
<ul>
<li><a href="/wiki/notes/Statin%20initiation/">Statin initiation</a></li>
<li><a href="/wiki/notes/amiodarone%20dosing/">amiodarone dosing</a></li>
<li><a href="/wiki/notes/DAPT/">DAPT</a></li>
</ul>
<h2>Pathology</h2>
<ul>
<li><a href="/wiki/notes/Valvular%20Diseases/">Valvular Diseases</a></li>
<li><a href="/wiki/notes/heart%20failure/">heart failure</a></li>
<li><a href="/wiki/notes/Cardiac%20Ischemia/">Cardiac Ischemia</a></li>
<li><a href="/wiki/notes/drug%20induced%20lower%20extremity%20edema/">drug induced lower extremity edema</a></li>
<li><a href="/wiki/notes/AAA/">AAA</a></li>
<li><a href="/wiki/notes/PAD/">PAD</a></li>
<li><a href="/wiki/notes/Hypertension/">Hypertension</a></li>
<li>[[s</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/heart failure 9-2 lecture/" class="peer">Heart Failure 9-2 Lecture</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>heart failure 9-2 lecture</h1>
<ul>
<li>related: <a href="/wiki/notes/Medicine/">Medicine</a>, <a href="/wiki/notes/Cardiology/">Cardiology</a>, <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<hr>
<h2>Definition</h2>
<ul>
<li>HFrEF: &lt;EF &lt; 40%</li>
<li>HFpEF: EF &gt; 50%,</li>
<li>Intermediate: HF with intermediate ejection 40-50%</li>
<li>EF normal does not mean CO is normal. Can have preserved EF but low CO</li>
</ul>
<h2>Classifications</h2>
<ul>
<li>NYHA: functional classification
<ul>
<li>1: no sx</li>
<li>2: sx with normal activity</li>
<li>3: sx with reduced activity</li>
<li>4: sx at rest</li>
</ul>
</li>
<li>ACC/AHA staging: more structural elements
<ul>
<li>A: high risk o</li>
</ul>
</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/athlete's heart can look like HCM/" class="peer">Athlete's Heart Can Look Like HCM</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>athlete's heart can look like HCM</h1>
<ul>
<li>related: <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<p>This patient's ECG findings – high-voltage QRS complexes and lateral repolarization abnormalities (inverted T waves) – are consistent with <strong>left ventricular hypertrophy (LVH)</strong>.  Young (age &lt;35) athletes can develop a physiologic increase in left ventricular wall thickness, cavity size, and myocardial mass in response to intense cardiovascular training.  This physiologic condition, termed <strong>athlete's heart</strong></p>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/monitoring heart function in chemotherapy/" class="peer">Monitoring Heart Function in Chemotherapy</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>monitoring heart function in chemotherapy</h1>
<ul>
<li>related: <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<p>Cardiotoxicity is one of the primary concerns when administering anthracycline chemotherapy agents, such as doxorubicin and daunorubicin.  The risk of cardiotoxicity with these agents is related to the cumulative dose, and is increased in patients with preexisting cardiac disease with a low ejection fraction.  In the general population, <strong>resting echocardiography</strong> is often used to evaluate ejection f</p>

      </div>
    </div>
  </li>
  
</ul>



</div>
    </div>

    <!-- <hr />
<p>Backlinks</p>


<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/trastuzumab and anthracycline/" class="peer">Trastuzumab and Anthracycline</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>trastuzumab and anthracycline</h1>
<ul>
<li>related: <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<!-- medication cardiomyopathy, anthracycline vs trastuzumab -->
<p>In most patients, trastuzumab-associated cardiotoxicity is <strong>reversible</strong>; there is complete recovery of cardiac function after treatment  discontinuation. In contrast, chronic anthracycline-associated  cardiotoxicity may not be reversible after treatment discontinuation due to myocyte necrosis, destruction, and replacement by fibrous tissue.</p>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Cardiology/" class="peer">Cardiology</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>Cardiology</h1>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2>Anatomy</h2>
<h2>Physiology</h2>
<ul>
<li><a href="/wiki/notes/EKG%20basics/">EKG basics</a></li>
<li><a href="/wiki/notes/SvO2/">SvO2</a></li>
<li><a href="/wiki/notes/cardiogenic%20shock/">cardiogenic shock</a></li>
</ul>
<h2>ECGs</h2>
<ul>
<li><a href="/wiki/notes/Arrythmia/">Arrythmia</a></li>
<li><a href="/wiki/notes/bundle%20branch%20blocks/">bundle branch blocks</a></li>
<li><a href="/wiki/notes/Brugada%20syndrome/">Brugada syndrome</a></li>
<li><a href="/wiki/notes/Wellens%20syndrome/">Wellens syndrome</a></li>
</ul>
<h2>Pharmacology</h2>
<ul>
<li><a href="/wiki/notes/Statin%20initiation/">Statin initiation</a></li>
<li><a href="/wiki/notes/amiodarone%20dosing/">amiodarone dosing</a></li>
<li><a href="/wiki/notes/DAPT/">DAPT</a></li>
</ul>
<h2>Pathology</h2>
<ul>
<li><a href="/wiki/notes/Valvular%20Diseases/">Valvular Diseases</a></li>
<li><a href="/wiki/notes/heart%20failure/">heart failure</a></li>
<li><a href="/wiki/notes/Cardiac%20Ischemia/">Cardiac Ischemia</a></li>
<li><a href="/wiki/notes/drug%20induced%20lower%20extremity%20edema/">drug induced lower extremity edema</a></li>
<li><a href="/wiki/notes/AAA/">AAA</a></li>
<li><a href="/wiki/notes/PAD/">PAD</a></li>
<li><a href="/wiki/notes/Hypertension/">Hypertension</a></li>
<li>[[s</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/heart failure 9-2 lecture/" class="peer">Heart Failure 9-2 Lecture</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>heart failure 9-2 lecture</h1>
<ul>
<li>related: <a href="/wiki/notes/Medicine/">Medicine</a>, <a href="/wiki/notes/Cardiology/">Cardiology</a>, <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<hr>
<h2>Definition</h2>
<ul>
<li>HFrEF: &lt;EF &lt; 40%</li>
<li>HFpEF: EF &gt; 50%,</li>
<li>Intermediate: HF with intermediate ejection 40-50%</li>
<li>EF normal does not mean CO is normal. Can have preserved EF but low CO</li>
</ul>
<h2>Classifications</h2>
<ul>
<li>NYHA: functional classification
<ul>
<li>1: no sx</li>
<li>2: sx with normal activity</li>
<li>3: sx with reduced activity</li>
<li>4: sx at rest</li>
</ul>
</li>
<li>ACC/AHA staging: more structural elements
<ul>
<li>A: high risk o</li>
</ul>
</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/athlete's heart can look like HCM/" class="peer">Athlete's Heart Can Look Like HCM</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>athlete's heart can look like HCM</h1>
<ul>
<li>related: <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<p>This patient's ECG findings – high-voltage QRS complexes and lateral repolarization abnormalities (inverted T waves) – are consistent with <strong>left ventricular hypertrophy (LVH)</strong>.  Young (age &lt;35) athletes can develop a physiologic increase in left ventricular wall thickness, cavity size, and myocardial mass in response to intense cardiovascular training.  This physiologic condition, termed <strong>athlete's heart</strong></p>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/monitoring heart function in chemotherapy/" class="peer">Monitoring Heart Function in Chemotherapy</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>monitoring heart function in chemotherapy</h1>
<ul>
<li>related: <a href="/wiki/notes/heart%20failure/">heart failure</a></li>
</ul>
<p>Cardiotoxicity is one of the primary concerns when administering anthracycline chemotherapy agents, such as doxorubicin and daunorubicin.  The risk of cardiotoxicity with these agents is related to the cumulative dose, and is increased in patients with preexisting cardiac disease with a low ejection fraction.  In the general population, <strong>resting echocardiography</strong> is often used to evaluate ejection f</p>

      </div>
    </div>
  </li>
  
</ul>


 -->

    <footer>
      <div class="max-w-6xl mb-10 text-sm text-center mt-96 ">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
